RMB 84.2 million, 84 sites, US$328 million: Hengrui took a drug with no story all the way to a marketing filing

On the Phase 3 results, there are currently two official statements.

The interim report of August 20 states: “The Company has completed the Phase III clinical study of HRG2010 for the treatment of Parkinson’s disease; the results support its improvement of motor fluctuations, with good safety and tolerability.”

The acceptance announcement of August 24 goes into more detail: this was “China’s first Phase III confirmatory study in Parkinson’s disease patients using carbidopa/levodopa extended-release tablets as the active comparator (HRG2010-301)”, randomized, double-blind, double-dummy and multicenter, with Professor Chen Haibo of Beijing Hospital as principal investigator and 84 sites nationwide taking part. The primary endpoint was change from baseline in mean daily “off” time at the end of the double-blind treatment period; the key secondary endpoint was change from baseline in mean daily “on” time without troublesome dyskinesia. The result: “Compared with the control group, HRG2010 capsules can shorten ‘off’ time and extend good ‘on’ time in Parkinson’s disease patients with motor fluctuations, and efficacy is maintained with long-term use. In terms of safety, HRG2010 capsules were consistent with the known profile of compound levodopa products, and no new safety signals were observed.”

So the accurate statement is: the positive direction and qualitative conclusion are public; the effect size, P-values and full safety data are not. The announcement attributes this passage to “compiled from study materials”, meaning it has not yet been peer-reviewed or published. To this day, the clinical trial registry has not posted results data for this study either.

This distinction matters. “Shortens ‘off’ time” is a direction; how many hours shorter, how large the difference from control, and whether it is statistically robust are what determine whether it can change prescribing habits. Until those numbers come out, any judgment of how good it is can only be conditional.

The core treatment for Parkinson’s disease is levodopa. The problem is its very short half-life: as the disease progresses to the middle and late stages, patients’ blood levels ride a roller coaster — when the drug is working it is called the “on” period; when it wears off and tremor and rigidity return, it is the “off” period. Clinically this is called motor fluctuation. The Chinese Guidelines for the Treatment of Parkinson’s Disease (5th edition) spell out the management path plainly: without increasing the total daily dose, increase dosing frequency and reduce individual doses, or switch to an extended-release formulation.

Translated: have patients take it more times a day. Some patients take it five or six times a day, timed precisely an hour before or an hour and a half after meals.

HRG2010 aims to solve exactly this. In the words of Hengrui’s interim report, it is “an innovative fixed-dose carbidopa and levodopa immediate-release/extended-release combination product” — one capsule contains two release units, immediate-release for fast onset and extended-release to prolong the effect. In the acceptance announcement the company classifies it as a “Class 2 new drug”, i.e. an improved new chemical drug.

The idea was not invented by Hengrui, and Hengrui says so frankly in its announcement: similar products already marketed in China and abroad mainly include carbidopa/levodopa extended-release tablets (brand name Sinemet CR), and Amneal’s RYTARY® and CREXONT®. Crexont was approved by FDA on August 7, 2024; Amneal’s official press release describes it as having “IR granules with carbidopa and levodopa for rapid onset of action, and ER pellets with levodopa for long-lasting efficacy”, and the same release states that patients on Crexont took it on average three times a day, versus five times a day for patients on immediate-release carbidopa/levodopa.

Now back to that key number. From project initiation to marketing filing, cumulative R&D investment in HRG2010 was about RMB 84.2 million.

For a cross-reference: among Hengrui products filed this year, SHR-1918 injection (for homozygous familial hypercholesterolemia) disclosed cumulative R&D investment of about RMB 242 million, and SHR-A2009 (for EGFR-mutant non-small cell lung cancer) about RMB 330 million. HRG2010’s investment is roughly a third of the former and a quarter of the latter. In a company whose 2025 R&D spending was RMB 8.724 billion, this project is on the order of one percent of a year’s R&D budget.

The development path was equally frugal, completed in three steps:

The start date differs slightly between the two registries: the international registry records November 6, 2024, while the Chinese registry’s first patient enrolled was December 16, 2024.

One combination of numbers here is worth pausing on: 165 patients, 84 sites — fewer than two patients per site on average.

From a clinical operations efficiency standpoint, this is not cost-effective — more sites mean higher start-up costs, monitoring costs and data consistency risks. But look at it another way: for a product that will depend on prescriptions from neurologists, and a company with almost no existing touchpoints in neurology, using one registration study to build in one go a network of 84 hospitals led by a national-level discipline leader changes the calculation entirely.

For a company like Hengrui that treats commercialization capability as a core asset, this is a very typical move.

Now for the contrast.

Open Hengrui’s 2025 annual report and HRG2010 appears in only one place: item 1 in the neuroscience column of Appendix 8, “Key Innovative Product Matrix”, as a text description. And in the same annual report —

• It is absent from Appendix 4, “Major follow-on clinical pipeline for marketed innovative drugs”, and Appendix 5, “Major clinical pipeline for innovative drugs in development”;
• It is absent from the roughly 53-item list in Appendix 6, “Innovative products and indications expected to be approved in the next three years (2026–2028)”;
• In the presentation at the J.P. Morgan Healthcare Conference in January 2026, the neuroscience page covered a Nav1.8 inhibitor, an anti-Aβ bispecific from the brain-penetrant platform, and stroke; the neuroscience-and-other row on the “Expected approvals 2026–2027” page listed cyclosporine A eye drops, a GnRH product and atropine eye drops — the words “Parkinson’s” did not appear.

By the 2026 interim report (pipeline data as of July 31, 2026), it was still absent from Appendices 4 and 5. Meanwhile febuxostat extended-release tablets, also an improved extended-release formulation, appear in the clinical pipeline appendices of both the annual and interim reports, and are even on the expected-launch list for 2027.

The annual report four-plus months earlier did not include it in the three-year launch forecast, and five months later it was filed for marketing. There is no secret here, just a very plain explanation: Hengrui’s disclosure volume on this asset is far lower than its actual rate of progress.

This is not an oversight; it looks more like a default classification habit. One sentence in Hengrui’s 2026 interim report makes the classification clear: “The Company has 26 Class 1 innovative drugs and 6 Class 2 new drugs approved and marketed in China” — Class 1 and Class 2 are two separate ledgers: Class 1 goes into the storyline, Class 2 goes into the product line. If approved, HRG2010 would be the 7th Class 2 new drug. It was never a shelved asset; it was simply never the protagonist.

For analysts, there is a lesson to take away here: absence from a pipeline chart does not mean a project is dead. To judge the real status of an improved asset, R&D investment disclosures and registration acceptances are far more reliable than investor materials.

The Phase 3 comparator was carbidopa/levodopa extended-release tablets, i.e. the originator Sinemet CR. From a registration standpoint this choice is entirely correct: for an improved new drug to prove clinical advantage, the cleanest approach is a head-to-head against an existing formulation of the same ingredients, and Hengrui did obtain the claim of “China’s first Phase III confirmatory study with carbidopa/levodopa extended-release tablets as active comparator”.

From a commercial standpoint, the choice is a bit awkward.

Carbidopa/levodopa extended-release/controlled-release tablets were for a long time sold in China only by the originator, and there were supply shortages. Domestic generics have been opening up in recent years: Shijiazhuang No.4 Pharmaceutical was the first to file in January 2023; according to public reports, Zhejiang Huahai was subsequently approved as a Class 4 generic deemed to have passed consistency evaluation, becoming the second domestic player, and companies such as Chongqing Huabang and Guangzhou Green Cross are still in the review queue. By the time HRG2010 completes review and actually launches, its reference product will no longer be the scarce, expensive import of years past, but a product leveled by domestic generics with prices steadily falling.

More importantly, this pond was never big. The mainstays of China’s anti-Parkinson’s drug market have never been carbidopa/levodopa extended-release tablets, but immediate-release benserazide/levodopa (Madopar), pramipexole, rasagiline and entacapone/carbidopa/levodopa. HRG2010 won in a small pond in Phase 3, but what it has to convert is the prescribing habits of a big pond.

Many people’s impression of the Parkinson’s field is still “old drugs dominate, nothing new for years”, but by 2026 that impression is no longer accurate. At launch HRG2010 will face three forces at once.

The first is similar improved products. Shanghai Wondroba Pharma’s WD-1603 is also a carbidopa/levodopa extended-release tablet and has completed a randomized, double-blind, placebo-controlled multicenter Phase 2 with low-, medium- and high-dose arms plus placebo. Notably, it chose early Parkinson’s patients, neatly offset from the mid-to-late-stage motor fluctuation population HRG2010 targets — which means the two will not collide head-on in the short term, but also that more than one company in China is working on “improving Parkinson’s treatment with extended-release compound levodopa”. In July 2024 the same company also filed a patent on a hot-melt granulated composition involving carbidopa and levodopa, paired with an oral delivery device that allows the granules to be placed in liquid and sipped.

The second is generics. Besides the domestic generics of carbidopa/levodopa extended-release tablets mentioned above, there is an even more telling example: safinamide mesylate tablets, a selective monoamine oxidase B inhibitor developed by Zambon, was only approved in China in December 2024, and since then a considerable number of domestic companies have filed generic applications; rotigotine patches also already have a domestic first generic approved (Kelun, filed as chemical Class 4). Generic response speed in this field in China is much faster than many imagine.

The third is alternative pathways. Physicians addressing “off” time have more options than switching formulations. Luye Pharma’s rotigotine extended-release microspheres for injection (brand name Jinyouping) was approved in June 2024 as the world’s first long-acting extended-release microsphere formulation for Parkinson’s disease, dosed once a week; it was also registered as an improved new drug, and went through the priority review pathway at the time. The COMT inhibitor opicapone capsules, in-licensed by Fosun Pharma from Bial, also has its China marketing application accepted. They compete with HRG2010 for the same clinical decision point — when a patient develops end-of-dose wearing-off, does the physician add an adjunctive tablet, switch to a long-acting delivery method, or swap the basic levodopa for an immediate/extended-release combination capsule?

Together, the implication of these three forces is clear: HRG2010’s window is not wide open, but narrowing. Its relative advantage is that it does not change the patient’s mode of administration — just swapping tablets for capsules and reducing the number of doses (exactly how few will only be known once full data and the final label are out) — and that is precisely the kind of advantage that is easiest to match.

This is the question a company like Hengrui has to answer first for any single product, and for HRG2010 the answer is split: channels are a great fit, while the department side will have to grow slowly out of those 84 sites.

First, the parts that fit.

Hengrui’s 2025 annual report discloses that at period end the company had a sales and marketing team of about 9,000 people (8,953 sales staff in the employee breakdown), with a sales network covering more than 25,000 hospitals and more than 200,000 offline retail pharmacies across more than 30 provincial-level regions in China; its professional prescription drug sales team covers all mainstream online pharmacy platforms, and it has set up a direct-to-patient (DTP) team. At the start of 2025 the company fully launched its “Channel Building Project”, explicitly aiming to bridge the “last mile” of chronic disease prevention and treatment and build a full-chain chronic disease ecosystem.

Parkinson’s disease is exactly that kind of typical chronic disease: diagnosis and first prescription in tertiary hospital neurology departments, followed by more than a decade of out-of-hospital refills and self-management, with much of the dispensing happening in retail and primary care. This infrastructure is a natural fit for the product, and something small and mid-sized improved-drug companies simply cannot build.

Next, the parts that need shoring up.

Hengrui has no marketed products in neurology. The company’s commercialization experience in neuroscience is concentrated in analgesia and anesthesia — the neuroscience disease areas highlighted in the annual report are “analgesia and anesthesia”, neurodegenerative diseases and stroke, and its marketed products target anesthesiology and the perioperative setting, not neurology outpatient clinics. The roughly 9,000-person team is configured for oncology, metabolism, immunology and anesthesia.

Those 84 Phase 3 sites are currently Hengrui’s most tangible asset in this department. Converting trial sites into prescribing sites requires continuity through post-marketing medical studies, academic meetings and real-world data, and Hengrui has that machine: the annual report discloses about 3,200 ongoing post-marketing medical research projects as of end-2025, covering a cumulative total of about 8,000 study sites, and 45 guidelines or consensus statements cited evidence on company products that year. Plugging HRG2010 into this machine is the most cost-effective step.

There is another hard constraint to acknowledge. Hengrui’s 2026 sales deployment reads: “concentrate resources to fully advance rapid access and hospital listing of innovative products”, with a full-year target to “strive for innovative drug sales growth of more than 30%”. In an organization that uses innovative drug growth as its core KPI, a Class 2 new drug neither enters the priority sequence for hospital listing of innovative products nor contributes to that growth curve — it will be structurally placed at the back of the line. This is not a matter of attitude; it is determined by how performance is measured. To get it moving, what is needed is a separate playbook that does not compete with Class 1 products for resources.

Hengrui’s quality and supply system is more than sufficient for this product. The annual report states that all production lines for the company’s marketed products have passed GMP inspections, that it holds about 20 overseas registration approvals covering injectables, oral formulations and inhaled anesthetics, and that products are sold in more than 50 countries; investor materials cite 12 advanced manufacturing plants. Carbidopa and levodopa are both mature APIs with a friendly cost structure, and domestic capacity has special significance for this category — the historical memory of this product in China is precisely shortages of the imported originator, so “stable supply” in itself can be a line that resonates with neurologists.

The only technical point worth watching is whether a multi-unit capsule combining immediate-release and extended-release units behaves consistently between clinical and commercial batches, and whether dissolution profiles remain stable after scale-up. The process difficulty of such products is concentrated in coating and particle size control. The two acceptance numbers (CXHS2600120, CXHS2600121) indicate at least two strengths were filed; the more complete the range of strengths, the easier it is for physicians to switch patients from existing multi-dose regimens — both a commercial advantage and more process consistency work.

HRG2010 is a mirror, reflecting a question every large Chinese pharma company faces in the same transition: when a company stakes its entire narrative on innovation and internationalization, where should it put products that are not innovative and cannot go global, but genuinely solve specific problems for Chinese patients?

Hengrui’s answer is already written in its actions — with RMB 84.2 million, three studies and 84 sites, it quietly pushed the product to the registration finish line, while giving it no leading role in any external material. This is not neglect but a kind of cost awareness: it is worth making, but not worth turning into a story.

The real test ahead is no longer on the R&D side either. When a category with a global ceiling of just over US$300 million, a price anchor being leveled by generics, and a department where Hengrui has no existing touchpoints are put together, how far this drug can go depends on whether those 84 sites can turn from research relationships into prescribing relationships, and whether the effect size is solid enough when the full data come out.

Taking a few fewer doses a day is a genuinely good thing for a patient who has lived with Parkinson’s disease for more than a decade. That good thing has already been taken as far as a marketing filing. The remaining question is whether a company with more than RMB 30 billion in revenue, betting its growth on 30% growth in innovative drugs, is willing to equip a product destined never to be the protagonist with a serious commercialization playbook.